Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has launched Nepexto in Australia, marking a significant expansion of access to biosimilar etanercept treatment for patients with autoimmune diseases. The launch represents the company's continued global market expansion strategy following vertical integration of its biosimilars business in 2022.
Partnership Strategy for Market Access
Nepexto will be promoted by Generic Health, Biocon Biologics' local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines. This partnership approach aims to expand access to patients across Australia, leveraging Generic Health's established distribution network and market presence.
Therapeutic Applications and Mechanism
Etanercept is a fusion-protein that inhibits tumor necrosis factor (TNF) and is used in the treatment of multiple autoimmune diseases. The therapeutic applications include rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. This broad indication profile positions Nepexto as a comprehensive treatment option for patients suffering from various inflammatory autoimmune conditions.
European Market Success and Global Expansion
Since receiving EU marketing authorization in 2020, Nepexto has earned broad adoption across Europe, establishing a strong foundation for international expansion. The successful European launch has provided valuable market validation and clinical experience that supports the Australian market entry.
According to the company's spokesperson, "Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto into new markets worldwide and further strengthen our immunology offering."
Company Portfolio and Performance
Biocon Biologics operates as a fully integrated, global biosimilars company with commercialized biosimilars in key emerging markets and advanced markets. The company maintains a robust pipeline of biosimilar assets under development across multiple therapeutic areas including diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases.
The parent company Biocon reported strong financial performance, with consolidated net profit surging 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24. This financial strength supports continued investment in global expansion initiatives and biosimilar development programs.
Nepexto is a registered trademark of Biosimilars New Co Limited, a Biocon Biologics Company, reflecting the company's strategic approach to intellectual property management and brand development in the biosimilars market.
